Red clover-derived isoflavones and mammographic breast density: a double blind, randomised, placebo-controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN42940165

Enrollment

205

Registered

2004-01-30

Start date

1997-05-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer Cancer Breast cancer

Interventions

Red clover-derived isoflavone tablet (26 mg biochanin A, 16 mg formononetin, 1 mg genistein and 0.5 mg daidzein) or placebo.

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Women aged 49 - 65 years 2. Wolfe's P2 or DY (dense parenchyma) mammographic breast patterns

Exclusion criteria

Exclusion criteria: Not provided at time of registration.

Design outcomes

Primary

Measure	Time frame
Change in: 1. Mammographic breast density 2. Serum oestradiol, FSH and LH 3. Menopausal symptoms 4. Lymphocyte tyrosine kinase activity Measured from baseline to 12 months.	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Apr 15, 2026